UPDATE: Jefferies Upgrades Health Management Associates to Buy on Multiple Expansion, Reform Momentum
Jefferies upgraded Health Management Associates (NYSE: HMA) from Hold to Buy and raised the price target from $7.50 to $14.50.
Jefferies analyst Brian Tanquilut commented, "We believe HMA shares still have meaningful upside left despite the stock's recent run given our view that sector multiples will continue to expand as key reform provisions take shape over the course of the next few months. As Medicaid expansion gains steam, especially in GOP-dominated states, and "exchange" pricing visibility improves, we expect HMA stock to continue rising."
Health Management Associates closed at $12.26 on Friday.
Latest Ratings for HMA
|Dec 2013||Wells Fargo||Downgrades||Outperform||Market Perform|
|Sep 2013||Avondale Partners||Downgrades||Market Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.